Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

MULTIVITAMINS FOR INFUSION

All injection strengths: general benefit

Multi 12/K1 Pediatric · DIN 02242529 · · injection-4mL+1mL vial

General benefitMarketed · checked 2026-09-20
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
No interchangeable product listed in the Ontario extract
Multi 12/K1 Pediatric · DIN 02242529 Manufacturer: Sandoz Canada Inc.; listing date 2019-04-30 Health Canada: Marketed since 2006-07-06 · brand MULTI-12/K1 PEDIATRIC · ATC B05XC VITAMINS · form Solution · route Intravenous · ingredients ASCORBIC ACID (ASCORBIC ACID) 80 MG/VIAL, VITAMIN A 2300 UNIT/VIAL, VITAMIN D 400 UNIT/VIAL, VITAMIN B1 (THIAMINE HYDROCHLORIDE) 1.2 MG/VIAL, VITAMIN B2 (RIBOFLAVIN-5-PHOSPHATE) 1.4 MG/VIAL, PYRIDOXINE HYDROCHLORIDE 1 MG/VIAL, NICOTINAMIDE 17 MG/VIAL, DEXPANTHENOL 5 MG/VIAL, VITAMIN E (DL-ALPHA TOCOPHERYL ACETATE) 7 UNIT/VIAL, VITAMIN K1 0.2 MG/VIAL, BIOTIN 20 MCG/VIAL, FOLIC ACID 140 MCG/VIAL, VITAMIN B12 (VITAMIN B12) 1 MCG/VIAL · company Sandoz canada incorporated · schedule Prescription
Check this DIN again · Health Canada product record

Multi 12/K1 Pediatric: Formulary list price $41.8000/unit (unit not stated in source; not the patient's cost)

Ministry pays: $41.8000 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=66277 · Verify on the e-Formulary ↗ (DIN 02242529)

Source record
DIN 02242529: Multi 12/K1 Pediatric Raw flags: sec3=Y Item: 882800056; group id 890; item number 2138; lccId None; manufacturer id SDZ Source form: Inj-4mL+1mL Vial Pk; strength: None Recorded listing: General benefit Source prices (unrounded): $41.8000; ministry $41.8000 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02242529 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=66277
Shortage status: not checked (no credentials)
Other drugs in the same formulary class (88:28 Multivitamins) and how they are covered

Matched class: 88:28 Multivitamins

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. No displayed product is listed as a general benefit in this extract. Check its listing requirements below. 88:28 Multivitamins

MULTIVITAMINS

· 4 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: · Tab Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 88:28
Full class listing Related classes: 88:08 Vitamin B, 88:12 Vitamin C, 88:16 Vitamin D Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
INDICATIONS AND CLINICAL USE Multi-12® is indicated for use as a supplement to parenteral nutrition for adults and children aged 11 and above. Its administration helps to maintain plasma vitamin levels and helps to prevent depletion of endogenous stores of the vitamins and development of subsequent deficiency symptoms. It is also indicated where there are increased requirements for vitamins due to stress situations such as surgery, extensive burns, fractures and other trauma, severe infectious diseases, and comatose states. Vitamin therapy should be initiated before development of clinical signs of vitamin deficiency. Patients with multiple vitamin deficiencies or with markedly increased requirements may be given multiples of the daily dosage for two or more days as indicated by the clinical status. https://pdf.hres.ca/dpd_pm/00082180.PDF PM date: OCT 23, 2025 Source product: MULTI 12; DIN 02100606; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.